Imaging Study to Investigate Safety and Diagnostic Performance of 18F rhPSMA 7.3 PET Ligand in Suspected Prostate Cancer Recurrence

NCT04186845 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

391

Enrollment

INDUSTRY

Sponsor class

Conditions

Prostate Cancer

Interventions

DRUG: rhPSMA-7.3 (18F) Injection
DIAGNOSTIC_TEST: Positron emission tomography scan

Sponsor

Blue Earth Diagnostics

Collaborators

[object Object]